Transition from IV to subcutaneous insulin US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Transition from IV to subcutaneous insulin. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Transition from IV to subcutaneous insulin US Medical PG Question 1: A 61-year-old female with congestive heart failure and type 2 diabetes is brought to the emergency room by her husband because of an altered mental status. He states he normally helps her be compliant with her medications, but he had been away for several days. On physical exam, her temperature is 37.2 C, BP 85/55, and HR 130. Serum glucose is 500 mg/dL. Which of the following is the first step in the management of this patient?
- A. IV ½ NS
- B. IV insulin
- C. Subcutaneous insulin injection
- D. IV NS (Correct Answer)
- E. IV D5W
Transition from IV to subcutaneous insulin Explanation: ***IV NS***
- The patient presents with **hypotension (85/55 mmHg)** and **tachycardia (130 bpm)**, indicating significant **volume depletion** despite a history of congestive heart failure.
- **Isotonic intravenous fluids (e.g., normal saline)** are crucial in the initial management of **diabetic ketoacidosis (DKA)** or **hyperosmolar hyperglycemic state (HHS)** to restore intravascular volume and improve tissue perfusion.
*IV ½ NS*
- **Hypotonic solutions** such as IV ½ NS are typically used later in DKA/HHS management, once the patient's **hemodynamic stability** has been achieved and serum sodium levels are stable or elevated.
- Administering hypotonic fluids to an already **hypotensive and volume-depleted patient** could worsen hypotension and potentially lead to cerebral edema if not carefully monitored.
*IV insulin*
- While insulin is essential for correcting hyperglycemia, it is administered **after or concurrently with fluid resuscitation** to avoid worsening hypovolemia as it drives glucose and potassium into cells, potentially causing **hypokalemia** and further **hemoconcentration**.
- **Fluid resuscitation** should always precede or be initiated simultaneously with insulin therapy, especially in cases of hemodynamic instability.
*Subcutaneous insulin injection*
- **Subcutaneous insulin** is not appropriate for initial management in this critically ill patient due to its **slower onset of action** and potentially **erratic absorption** in hypotensive and poorly perfused states.
- **Intravenous insulin** is preferred in DKA/HHS for its rapid, titratable effect.
*IV D5W*
- **Dextrose 5% in water (D5W)** is a hypotonic solution primarily used when **blood glucose levels fall below 250 mg/dL** during DKA/HHS treatment to prevent hypoglycemia.
- Administering D5W in a patient with a **serum glucose of 500 mg/dL** would further elevate blood sugar and worsen the hyperosmolar state.
Transition from IV to subcutaneous insulin US Medical PG Question 2: An otherwise healthy 14-year-old girl is brought to the emergency room by her father because of excessive thirst, excessive urination, and weight loss. Her symptoms started acutely 5 days ago. Vital signs reveal a temperature of 36.6°C (97.8°F), blood pressure of 100/65 mm Hg, and pulse of 105/min. Physical examination shows a thin girl with dry mucous membranes but normal skin turgor. Laboratory results are shown:
Random blood sugar 410 mg/dL
C-peptide undetectable
Serum beta-hydroxybutyrate negative
Which of the following is the best initial therapy for this patient?
- A. Metformin
- B. Glimepiride
- C. Pramlintide
- D. Basal-bolus insulin (Correct Answer)
- E. Intravenous fluids, insulin infusion, and correction of electrolytes
Transition from IV to subcutaneous insulin Explanation: ***Basal-bolus insulin***
- This patient presents with **polyuria**, **polydipsia**, **weight loss**, **undetectable C-peptide**, and **severe hyperglycemia (410 mg/dL)**, consistent with **new-onset Type 1 Diabetes Mellitus**.
- Critically, the **beta-hydroxybutyrate is negative**, indicating this patient is **NOT in diabetic ketoacidosis (DKA)**.
- For new-onset Type 1 diabetes without ketoacidosis, the appropriate initial therapy is **subcutaneous basal-bolus insulin** regimen (long-acting basal insulin plus rapid-acting insulin with meals).
- The patient needs rehydration (which can be oral or IV) and insulin initiation, but does not require intensive care with insulin infusion since there is no ketoacidosis.
*Intravenous fluids, insulin infusion, and correction of electrolytes*
- This is the standard management for **diabetic ketoacidosis (DKA)** or **hyperosmolar hyperglycemic state (HHS)**.
- However, this patient has **negative beta-hydroxybutyrate**, ruling out DKA, and therefore does not require insulin infusion.
- Insulin infusion is reserved for critically ill patients with ketoacidosis or severe metabolic derangements requiring intensive monitoring.
*Metformin*
- **Metformin** is an oral hypoglycemic agent used primarily for **Type 2 Diabetes Mellitus**.
- It works by reducing hepatic glucose production and improving insulin sensitivity, but is not effective in Type 1 diabetes with absolute insulin deficiency.
- The **undetectable C-peptide** confirms this patient has no endogenous insulin production and requires exogenous insulin.
*Glimepiride*
- **Glimepiride** is a **sulfonylurea** that stimulates insulin release from pancreatic beta cells.
- It would not be effective in this patient due to **undetectable C-peptide**, indicating minimal to no functional beta cells.
- This medication is used in Type 2 diabetes, not Type 1 diabetes.
*Pramlintide*
- **Pramlintide** is an **amylin analog** used as adjunctive therapy in Type 1 and Type 2 diabetes to slow gastric emptying and suppress glucagon secretion.
- It is not a primary treatment for diabetes and would not address the fundamental issue of insulin deficiency.
- It must be used in conjunction with insulin therapy and is not appropriate as initial monotherapy.
Transition from IV to subcutaneous insulin US Medical PG Question 3: A 35-year-old woman is started on a new experimental intravenous drug X. In order to make sure that she is able to take this drug safely, the physician in charge of her care calculates the appropriate doses to give to this patient. Data on the properties of drug X from a subject with a similar body composition to the patient is provided below:
Weight: 100 kg
Dose provided: 1500 mg
Serum concentration 15 mg/dL
Bioavailability: 1
If the patient has a weight of 60 kg and the target serum concentration is 10 mg/dL, which of the following best represents the loading dose of drug X that should be given to this patient?
- A. 300 mg
- B. 450 mg
- C. 150 mg
- D. 1000 mg
- E. 600 mg (Correct Answer)
Transition from IV to subcutaneous insulin Explanation: ***600 mg***
- First, calculate the **volume of distribution (Vd)** using the provided data: **Vd = Total Dose / Serum Concentration**. Converting units: 15 mg/dL = 150 mg/L. Therefore, Vd = 1500 mg / 150 mg/L = **10 L** (for the 100 kg subject).
- Since the Vd value is for a 100 kg person, Vd per kg = 10 L / 100 kg = **0.1 L/kg**. For the 60 kg patient, the Vd = 0.1 L/kg × 60 kg = **6 L**.
- The **loading dose = Target Serum Concentration × Vd / Bioavailability**. Converting target concentration: 10 mg/dL = 100 mg/L. Therefore: (100 mg/L × 6 L) / 1 = **600 mg**.
*300 mg*
- This value is obtained if an incorrect **Vd** or target concentration was used, potentially through miscalculation or incorrect unit conversion.
- For instance, if the **Vd** was inaccurately calculated at 3 L (instead of 6 L), this could lead to the incorrect answer.
*450 mg*
- This result might occur if the **Vd calculation** was flawed or if the target concentration was incorrectly interpreted.
- A potential error could involve using a Vd of 4.5 L which would result in 450 mg, or if the drug amount was simply prorated by weight without properly considering the Vd per kg.
*150 mg*
- This value suggests a significant error in the calculation of the **volume of distribution** or the target concentration.
- It might be obtained if the **Vd** was mistakenly taken as 1.5 L or if the dose was divided by the original serum concentration without accounting for the new patient's weight and desired concentration.
*1000 mg*
- This value is significantly higher than the correct answer, indicating an overestimation of the **Vd** or target concentration.
- It could result from using the original dose (1500 mg) and attempting to scale it incorrectly by weight alone (1500 mg × 60/100 = 900 mg, close to 1000), or if unit conversions were mishandled during the Vd determination.
Transition from IV to subcutaneous insulin US Medical PG Question 4: A 42-year-old man presents to his primary care physician for preventative care. He does not have any current complaint. His father died of diabetic nephropathy. Vital signs include a temperature of 36.7°C (98.06°F), blood pressure of 150/95 mm Hg, and pulse of 90/min. His fasting blood glucose is 159 mg/dL (on 2 occasions) and HbA1c is 8.1%. The patient is started on metformin and lifestyle modifications. 3 months later, he comes for a follow-up visit. His serum blood glucose is 370 mg/dL and HbA1C is 11%. The patient currently complains of weight loss and excessive urination. Which of the following is the optimal therapy for this patient?
- A. A thiazolidinedione added to metformin
- B. Basal-bolus insulin (Correct Answer)
- C. Basal insulin added to metformin
- D. A sulfonylurea added to metformin
- E. A sodium-glucose cotransporter 2 inhibitor added to metformin
Transition from IV to subcutaneous insulin Explanation: ***Basal-bolus insulin***
- This patient presents with an HbA1C of 11% and symptoms of **polyuria** and **weight loss**, indicating significant hyperglycemia. Due to the high HbA1c and symptomatic presentation despite initial metformin and lifestyle modifications, **aggressive glucose lowering** is required to prevent acute complications and long-term organ damage.
- Basal-bolus insulin therapy provides both continuous basal insulin to control fasting glucose and prandial boluses to manage post-meal glucose spikes, offering the most comprehensive and effective glucose control in severe hyperglycemia.
*A thiazolidinedione added to metformin*
- Thiazolidinediones (TZDs) like pioglitazone improve insulin sensitivity and are used as a second-line agent, but they have a **slow onset of action** and are generally insufficient for patients with such severe hyperglycemia (HbA1c 11%).
- TZDs can take several weeks to reach maximal effect and are not potent enough for immediate and significant glucose reduction in symptomatic patients with markedly elevated HbA1c.
*Basal insulin added to metformin*
- While adding basal insulin to metformin is a common step for patients whose HbA1c is a few points above target, an HbA1c of 11% with symptoms of weight loss and polyuria indicates **more severe insulin deficiency** or resistance requiring more comprehensive insulin replacement.
- Basal insulin alone would not adequately address post-prandial hyperglycemia, which is likely contributing significantly to the overall high HbA1c.
*A sulfonylurea added to metformin*
- Sulfonylureas stimulate insulin release from pancreatic beta cells, but their efficacy is limited, and they carry a risk of **hypoglycemia** and weight gain.
- Given the patient's very high HbA1c of 11%, sulfonylureas would likely be insufficient to achieve target glycemic control and might lead to significant side effects without achieving adequate glucose lowering.
*A sodium-glucose cotransporter 2 inhibitor added to metformin*
- SGLT2 inhibitors promote glucose excretion in the urine and offer cardiovascular and renal benefits, but they are generally less potent in reducing HbA1c compared to insulin, especially in patients with severe hyperglycemia.
- While beneficial for some, they would not provide the rapid and substantial glucose reduction needed for a patient with an HbA1c of 11% and acute symptoms.
Transition from IV to subcutaneous insulin US Medical PG Question 5: A 14-year-old female with no past medical history presents to the emergency department with nausea and abdominal pain. On physical examination, her blood pressure is 78/65, her respiratory rate is 30, her breath has a fruity odor, and capillary refill is > 3 seconds. Serum glucose is 820 mg/dL. After starting IV fluids, what is the next best step in the management of this patient?
- A. Intravenous Dextrose in water
- B. Subcutaneous insulin glargine
- C. Intravenous regular insulin (Correct Answer)
- D. Intravenous glucagon
- E. Subcutaneous insulin lispro
Transition from IV to subcutaneous insulin Explanation: ***Intravenous regular insulin***
- The patient presents with **diabetic ketoacidosis (DKA)**, characterized by **hyperglycemia**, **fruity breath** (due to ketones), and **hypotension**. Prompt administration of **intravenous regular insulin** is crucial to lower blood glucose and resolve ketoacidosis.
- **Regular insulin** is preferred intravenously due to its **rapid onset** and short duration of action, allowing for precise titration and continuous adjustment based on glucose levels.
*Intravenous Dextrose in water*
- **Dextrose** would further increase the already severely elevated blood glucose level in a patient with DKA, worsening the metabolic derangements.
- Dextrose is typically initiated only after blood glucose drops to safe levels (<200 mg/dL) to prevent **hypoglycemia** during insulin infusion.
*Subcutaneous insulin glargine*
- **Insulin glargine** is a **long-acting insulin** designed for basal insulin coverage, not for acute management of severe hyperglycemia or DKA.
- Its **slow onset of action** and prolonged effect make it unsuitable for the urgent and rapid glucose reduction required in DKA.
*Intravenous glucagon*
- **Glucagon** is a hormone that **raises blood glucose levels**, counteracting the effects of insulin.
- Administering glucagon would exacerbate the severe hyperglycemia present in DKA and is used only in cases of severe hypoglycemia.
*Subcutaneous insulin lispro*
- **Insulin lispro** is a **rapid-acting insulin analog** but is typically given subcutaneously.
- While faster than regular insulin subcutaneously, the **subcutaneous route** has variable absorption in critically ill patients, and the immediate and precisely controllable effect of intravenous regular insulin is needed in DKA.
Transition from IV to subcutaneous insulin US Medical PG Question 6: An experimental drug, ES 62, is being studied. It prohibits the growth of vancomycin-resistant Staphylococcus aureus. It is highly lipid-soluble. The experimental design is dependent on a certain plasma concentration of the drug. The target plasma concentration is 100 mmol/dL. Which of the following factors is most important for calculating the appropriate loading dose?
- A. Volume of distribution (Correct Answer)
- B. Half-life of the drug
- C. Therapeutic index
- D. Clearance of the drug
- E. Rate of administration
Transition from IV to subcutaneous insulin Explanation: **Volume of distribution**
- The **loading dose** is primarily determined by the desired **plasma concentration** and the **volume of distribution (Vd)**, as it reflects how extensively a drug is distributed in the body.
- The formula for loading dose is: Loading Dose = (Target Plasma Concentration × Vd).
*Half-life of the drug*
- The **half-life** is crucial for determining the **dosing interval** and the time it takes to reach **steady-state concentrations**, not the initial loading dose.
- It reflects the rate at which the drug is eliminated from the body.
*Therapeutic index*
- The **therapeutic index** is a measure of a drug's relative safety, indicating the ratio between the **toxic dose** and the **effective dose**.
- While important for drug safety, it does not directly determine the magnitude of the loading dose itself.
*Clearance of the drug*
- **Clearance** is the rate at which the drug is removed from the body and is a primary determinant of the **maintenance dose** required to sustain a desired plasma concentration.
- It does not directly calculate the initial loading dose needed to achieve an immediate target concentration.
*Rate of administration*
- The **rate of administration** (e.g., infusion rate) primarily influences how quickly the drug reaches its target concentration, but not the total quantity of drug needed for the initial loading dose.
- It affects the kinetics of how the loading dose achieves the target concentration, rather than defining the dose amount.
Transition from IV to subcutaneous insulin US Medical PG Question 7: An 8-year old boy is brought to the emergency department because he has been lethargic and has had several episodes of nausea and vomiting for the past day. He has also had increased thirst over the past two months. He has lost 5.4 kg (11.9 lbs) during this time. He is otherwise healthy and has no history of serious illness. His temperature is 37.5 °C (99.5 °F), blood pressure is 95/68 mm Hg, pulse is 110/min, and respirations are 30/min. He is somnolent and slightly confused. His mucous membranes are dry. Laboratory studies show:
Hemoglobin 16.2 g/dL
Leukocyte count 9,500/mm3
Platelet count 380,000/mm3
Serum
Na+ 130 mEq/L
K+ 5.5 mEq/L
Cl- 99 mEq/L
HCO3- 16 mEq/L
Creatinine 1.2 mg/dL
Glucose 570 mg/dL
Ketones positive
Blood gases, arterial
pH 7.25
pCO2 21 mm Hg
Which of the following is the most appropriate next step in management?
- A. Intravenous hydration with 0.45% normal saline and insulin
- B. Intravenous hydration with 5% dextrose solution and 0.45% normal saline
- C. Intravenous sodium bicarbonate
- D. Intravenous hydration with 0.9% normal saline and insulin (Correct Answer)
- E. Intravenous hydration with 0.9% normal saline and potassium chloride
Transition from IV to subcutaneous insulin Explanation: ***Intravenous hydration with 0.9% normal saline and insulin***
- This patient presents with **diabetic ketoacidosis (DKA)**, characterized by hyperglycemia (glucose 570 mg/dL), metabolic acidosis (pH 7.25, HCO3- 16 mEq/L, ketones positive), and dehydration (dry mucous membranes, increased thirst, weight loss).
- Initial management of DKA involves aggressive **volume expansion** with **0.9% normal saline** to restore perfusion and reduce hyperglycemia; subsequently, **insulin infusion** is started to correct hyperglycemia and halt ketogenesis.
*Intravenous hydration with 0.45% normal saline and insulin*
- While insulin is crucial, **0.45% normal saline (hypotonic saline)** is generally not the initial fluid of choice for DKA due to the risk of exacerbating cerebral edema, especially in children.
- **Isotonic saline (0.9% normal saline)** is preferred for initial resuscitation to rapidly restore extracellular fluid volume.
*Intravenous hydration with 5% dextrose solution and 0.45% normal saline*
- **5% dextrose solution** should only be added to intravenous fluids when the blood glucose level falls to around 200-250 mg/dL, to prevent hypoglycemia while continuing insulin to resolve ketosis.
- Administering dextrose initially would worsen the existing severe hyperglycemia.
*Intravenous sodium bicarbonate*
- **Sodium bicarbonate** is generally not recommended for mild to moderate DKA due to potential risks like cerebral edema and metabolic alkalosis, and potential paradoxical worsening of CNS acidosis.
- Bicarbonate therapy is reserved for **severe acidosis (pH < 6.9 or 7.0)** with hemodynamic instability or impaired cardiac contractility, which is not the case here.
*Intravenous hydration with 0.9% normal saline and potassium chloride*
- While **0.9% normal saline** is appropriate, this option lacks **insulin therapy**, which is essential for treating DKA by halting ketogenesis and correcting hyperglycemia.
- Although potassium supplementation will be necessary during DKA treatment (as insulin drives K+ into cells and can cause hypokalemia), the most appropriate **next step** is to initiate both fluid resuscitation and insulin therapy together.
- The patient's current potassium level of 5.5 mEq/L is at the upper limit of normal, but reflects total body potassium depletion; potassium should be added to maintenance fluids once adequate urine output is established.
Transition from IV to subcutaneous insulin US Medical PG Question 8: A 48-year-old man presents with DKA. Initial treatment is initiated with fluids and insulin infusion. Labs show glucose 460 mg/dL, pH 7.18, bicarbonate 10 mEq/L, potassium 4.5 mEq/L, and creatinine 2.8 mg/dL (baseline 1.0). After 4 hours, glucose decreases to 380 mg/dL but pH worsens to 7.12, bicarbonate drops to 8 mEq/L, and lactate is 5.2 mmol/L (initially 1.8). Blood pressure is 85/50 mmHg. Evaluate the clinical situation and necessary intervention.
- A. Administer additional fluid bolus for persistent hypotension
- B. Evaluate for sepsis or other concurrent illness causing lactic acidosis (Correct Answer)
- C. Increase insulin infusion rate to accelerate ketone clearance
- D. Add bicarbonate therapy for worsening acidosis
- E. Continue current management as DKA takes time to resolve
Transition from IV to subcutaneous insulin Explanation: ***Evaluate for sepsis or other concurrent illness causing lactic acidosis***
- While the blood glucose is responding to insulin, the **worsening metabolic acidosis** and significantly elevated **lactate (5.2 mmol/L)** indicate a secondary process such as **sepsis** or tissue hypoperfusion.
- **Diabetic Ketoacidosis (DKA)** often has a precipitating factor; the combination of **hypotension** and rising lactate suggests **septic shock** or organic ischemia that requires urgent investigation and targeted treatment.
*Administer additional fluid bolus for persistent hypotension*
- Although fluid resuscitation is vital, simply giving more fluids without diagnosing the **underlying cause** of the rising lactate and refractory shock is insufficient.
- **Hypotension** in this context may be secondary to **septic shock** or systemic inflammatory response rather than simple volume depletion from DKA.
*Increase insulin infusion rate to accelerate ketone clearance*
- The current insulin infusion is successfully lowering the blood glucose, but the acidosis is worsening due to **lactic acid**, not just ketones.
- Increasing insulin will not resolve **Type A lactic acidosis** caused by **inadequate tissue oxygenation** or sepsis.
*Add bicarbonate therapy for worsening acidosis*
- **Bicarbonate therapy** is generally not recommended in DKA unless the pH is <6.9, as it can cause **paradoxical cerebral acidosis** and hypokalemia.
- Administering bicarbonate would provide a temporary buffer but would fail to address the **rising lactate** and underlying hemodynamic instability.
*Continue current management as DKA takes time to resolve*
- While DKA resolution is gradual, a **rising lactate** and **falling pH** despite therapy are red flags that indicate the clinical condition is deteriorating.
- Ignoring the **acute kidney injury** (Creatinine 2.8) and persistent **hypotension** increases the risk of multi-organ failure and mortality.
Transition from IV to subcutaneous insulin US Medical PG Question 9: A 25-year-old woman with type 1 diabetes presents with DKA. She admits to intentionally withholding insulin to lose weight. This is her fifth DKA admission in 8 months. Current pH is 7.14, glucose 520 mg/dL, bicarbonate 11 mEq/L. Medical costs exceed $150,000 for recurrent admissions. The team is frustrated. Evaluate the comprehensive management approach beyond acute DKA treatment.
- A. Referral to ethics committee for discussion of resource allocation
- B. Involuntary psychiatric commitment for non-compliance
- C. Insulin pump placement to prevent future manipulation
- D. Multidisciplinary approach including psychiatry, eating disorder specialist, diabetes educator, and close outpatient follow-up (Correct Answer)
- E. Standard DKA treatment with discharge to outpatient endocrinology
Transition from IV to subcutaneous insulin Explanation: ***Multidisciplinary approach including psychiatry, eating disorder specialist, diabetes educator, and close outpatient follow-up***
- This patient presents with **diabulimia**, a life-threatening eating disorder where Type 1 diabetics restrict insulin for weight control, requiring a **comprehensive care team** to address both physiologic and psychological needs.
- A **multidisciplinary strategy** is essential to reduce the high risk of mortality and frequent **recurrent DKA admissions** by targeting the root cause of non-compliance.
*Referral to ethics committee for discussion of resource allocation*
- While medical costs are high, **withholding treatment** based on cost or resource allocation for a life-threatening condition like DKA is generally unethical.
- The **ethics committee** may assist in complex care plans, but it does not address the primary clinical need for specialized psychiatric and nutritional intervention.
*Involuntary psychiatric commitment for non-compliance*
- **Involuntary commitment** typically requires the patient to be a danger to themselves or others due to a mental illness; insulin omission, while dangerous, often does not meet legal criteria if the patient has **decision-making capacity**.
- Simple **non-compliance** in an adult with capacity is not usually grounds for commitment, and long-term behavioral change is better achieved through voluntary therapeutic engagement.
*Insulin pump placement to prevent future manipulation*
- An **insulin pump** is not a solution as it can still be easily manipulated, disconnected, or the settings altered by a patient determined to restrict insulin.
- Introducing a medical device without addressing the **underlying eating disorder** may actually complicate management and increase the risk of device-related complications.
*Standard DKA treatment with discharge to outpatient endocrinology*
- Given five DKA admissions in 8 months, standard management has already proven **insufficient** and fails to address the unique psychiatric etiology of her condition.
- Discharging to **standard outpatient endocrinology** without specialized eating disorder support ignores the behavioral triggers that lead to recurrent life-threatening metabolic crises.
Transition from IV to subcutaneous insulin US Medical PG Question 10: A 55-year-old man with type 2 diabetes and end-stage renal disease on hemodialysis presents with DKA. Initial glucose is 580 mg/dL, pH 7.12, bicarbonate 10 mEq/L, and potassium 6.2 mEq/L. He is fluid overloaded with bilateral crackles and peripheral edema. His last dialysis was 3 days ago. Evaluate the optimal management strategy addressing both DKA and renal failure.
- A. Standard DKA protocol with furosemide for fluid management
- B. Bicarbonate therapy to correct acidosis without fluids
- C. Subcutaneous insulin with no IV fluids due to volume overload
- D. Insulin infusion with limited fluids and urgent hemodialysis (Correct Answer)
- E. Standard DKA protocol with aggressive fluid resuscitation
Transition from IV to subcutaneous insulin Explanation: ***Insulin infusion with limited fluids and urgent hemodialysis***
- Patients with **ESRD** and **DKA** who are **fluid overloaded** require **urgent hemodialysis** to safely correct metabolic acidosis, hyperkalemia, and volume status.
- **Continuous insulin infusion** is essential to stop ketone production, but fluid resuscitation must be severely **restricted** to avoid worsening pulmonary edema.
*Standard DKA protocol with furosemide for fluid management*
- **Furosemide** is ineffective in patients with **end-stage renal disease** (ESRD) as they have minimal to no residual renal function.
- Standard DKA protocols prioritize aggressive IV fluids, which would be **life-threatening** for a patient already showing signs of volume overload and crackles.
*Bicarbonate therapy to correct acidosis without fluids*
- **Bicarbonate therapy** is generally not recommended for DKA unless the pH is below 6.9, and it can cause a **rebound worsening** of intracellular acidosis.
- It does not address the underlying **insulin deficiency** or the patient's massive **volume overload** and hyperkalemia.
*Subcutaneous insulin with no IV fluids due to volume overload*
- **Subcutaneous insulin** is inappropriate for severe DKA (pH 7.12); **intravenous insulin** is the standard for rapid titration and metabolic control.
- Complete avoidance of fluids may prevent correction of the **osmotic shift**, but the primary failure here is the omission of dialysis for a symptomatic ESRD patient.
*Standard DKA protocol with aggressive fluid resuscitation*
- Aggressive fluid administration is **contraindicated** in ESRD patients with clinical signs of **congestive heart failure** like crackles and peripheral edema.
- This approach carries a high risk of inducing **acute respiratory failure** or flash pulmonary edema.
More Transition from IV to subcutaneous insulin US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
